Paradigm Biocapital Advisors LP Kura Oncology, Inc. Transaction History
Paradigm Biocapital Advisors LP
- $2.77 Billion
- Q3 2024
A detailed history of Paradigm Biocapital Advisors LP transactions in Kura Oncology, Inc. stock. As of the latest transaction made, Paradigm Biocapital Advisors LP holds 4,331,321 shares of KURA stock, worth $68.9 Million. This represents 3.05% of its overall portfolio holdings.
Number of Shares
4,331,321
Previous 4,539,381
4.58%
Holding current value
$68.9 Million
Previous $93.5 Million
9.45%
% of portfolio
3.05%
Previous 3.78%
Shares
6 transactions
Others Institutions Holding KURA
# of Institutions
185Shares Held
81.8MCall Options Held
42.1KPut Options Held
34K-
Suvretta Capital Management, LLC New York, NY7.65MShares$122 Million5.88% of portfolio
-
Black Rock Inc. New York, NY6.97MShares$111 Million0.0% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA5.81MShares$92.4 Million4.92% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY5.41MShares$86.1 Million1.97% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.2MShares$66.9 Million0.0% of portfolio
About Kura Oncology, Inc.
- Ticker KURA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 66,893,000
- Market Cap $1.06B
- Description
- Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A p...